person · Reporting owner
Inglis Tiffany Eul Davis
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SERA PROGNOSTICS, INC.SERA · Entity 304 | Chief Medical Officer | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SERA PROGNOSTICS, INC.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 83,565 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 8,024 · Balance 83,565 F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $2.03 to $2.05, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $2.03 to $2.05, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 21:06 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 8,024 | $2.03 | $16,288.72 |
DisclosureSEC source: 0002091798-26-000010 · ownership.xml · nonDerivative · entry 1 Inglis Tiffany Eul Davis · CIK 0002091798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,565 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $2.03 to $2.05, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:07 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 486 | $2.00 | $972.00 |
DisclosureSEC source: 0002091798-26-000008 · ownership.xml · nonDerivative · entry 1 Inglis Tiffany Eul Davis · CIK 0002091798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,589 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $2.00 to $2.03, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:08 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 362 | $2.01 | $727.62 |
DisclosureSEC source: 0002091798-26-000004 · ownership.xml · nonDerivative · entry 1 Inglis Tiffany Eul Davis · CIK 0002091798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,075 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $1.87 to $2.12, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| March 12, 2026 Filed Mar 13, 2026 22:28 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 27,034 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001193125-26-106590 · ownership.xml · derivative · entry 2 Inglis Tiffany Eul Davis · CIK 0002091798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,034 Underlying: Class A Common Stock · 27,034 shares Expires 2036-03-12 F2 · derivative.exercise_date: These stock options vest over four years as follows: 1/48 of the original grant amount vests in monthly installments for four years following the vesting commencement date, which is March 10, 2026, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| March 12, 2026 Filed Mar 13, 2026 22:28 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 17,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-106590 · ownership.xml · nonDerivative · entry 1 Inglis Tiffany Eul Davis · CIK 0002091798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,437 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over four years as follows: 1/16 of the original grant amount vests in quarterly installments for four years following the vesting commencement date, which is March 10, 2026, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 23:12 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 107,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001193125-25-240530 · ownership.xml · derivative · entry 2 Inglis Tiffany Eul Davis · CIK 0002091798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,000 Underlying: Class A Common Stock · 107,000 shares Expires 2035-10-15 F2 · derivative.exercise_date: These stock options vest over four years as follows: 25% of the original grant amount vests on the first anniversary of the vesting commencement date, which is October 10, 2025, and 1/36 of the remaining amount vests in monthly installments for three years thereafter, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 23:12 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-240530 · ownership.xml · nonDerivative · entry 1 Inglis Tiffany Eul Davis · CIK 0002091798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over four years as follows: 25% of the original grant amount vests on the first anniversary of the vesting commencement date, which is October 10, 2025, and 1/12 of the remaining amount vests in quarterly installments for three years thereafter, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.